Subclinical neuropathy among diabetes control and complications trial participants without diagnosable neuropathy at trial completion: Possible predictors of incident neuropathy?

Diabetes Care

Volumn 30, Issue 10, 2007, Pages 2613-2618

  Albers, James W ^a,b   Herman, William H ^a   Pop Busui, Rodica ^a   Martin, Catherine L ^a   Cleary, Patricia ^a   Waberski, Barbara ^a  

^a Epidemiology of Diabetes Intervention and Complications Research Group   (United States)

^b DCCT/EDIC Research Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIABETIC NEPHROPATHY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ELECTRODIAGNOSIS; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NERVE CONDUCTION; OUTCOME ASSESSMENT; RISK FACTOR; SYMPTOM; TREATMENT OUTCOME;

DIABETES MELLITUS; DIABETIC NEUROPATHIES; ELECTROPHYSIOLOGY; FOLLOW-UP STUDIES; HUMANS; NEURAL CONDUCTION; PREVALENCE;

EID: 35148833511     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-0850     Document Type: Article

References (15)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group: Epidemiology of Diabetes Interventions and Complications (EDIC) design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22:99-111, 1999
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342:381-389, 2000
4. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563-2569, 2002
5. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290:2159-2167, 2003
6. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653, 2005
7. Martin CL, Albers J, Herman WH, Cleary P, Waberski B, Greene DA, Stevens MJ, Feldman EL, DCCT/EDIC Research Group: Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 29:340-344, 2006
8. The Diabetes Control and Complications Trial Research Group: Effect of intensive diabetes treatment on nerve conduction in the Diabetes Control and Complications Trial. Ann Neurol 38:869-880, 1995
9. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 18:361-376, 1995
10. Wald JJ, Albers JW, Simmons Z, Roberts JA, Capo B: Cisplatin neuropathy: clinical and nerve conduction correlation. Muscle Nerve 17:1116-1117, 1994
11. Albers JW, Berent S: Cisplatin. In Neurobehavioral Toxicology: Neurological and Neuropsychological Perspectives. London and New York, Taylor & Francis, 2005, p. 431-436
12. Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD: Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 24:1050-1057, 2001
13. Stetson DS, Albers JW, Silverstein BA, Wolfe RA: Effects of age, sex, and anthropometric factors on nerve conduction measures. Muscle Nerve 15:1095-1104, 1992
14. Dyck PJ, O'Brien PC: Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy. Diabetes Care 12:649-652, 1989
15. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group, Jacobson AM, Ryan CM, Cleary P, Waberski B, Burwood A, Weinger K, Bayless M, Dahms W, Silvers N: Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 356:1842-1852, 2007